Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study

Stephen O. Brennan, MB[1,2], Peter J. Kelly MD[1,3,4], Sarah Gorey, MB[3], Pádraig Synnott, MB[3], Dipender Gill, BMBCh PhD,[5] Martin Dichgans, MD[6,7,8], Marios K. Georgakis, MD PhD[6,9,10], Marie-Joe Dib, PhD[11], Eloi Gagnon, MA[12], Niall Mahon, MB[13], Gavin J. Blake, MB[13], Christina Jern, PhD[14,15], Hugh S. Markus, PhD[16], William Whiteley PhD[17,18], John J. McCabe, MB PhD[3,4,19].

1. Stroke Service, Department of Neurology, Mater Misericordiae University Hospital, Dublin, Ireland
2. School of Medicine, University of Galway, Galway, Ireland
3. Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland,
4. School of Medicine, University College Dublin, Dublin, Ireland
5. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
6. Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
7. German Center for Neurodegenerative Disease, Munich, Germany
8. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
9. Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
10. Program in Medical and Population Genetics, Broad Institute of Harvard and the Massachusetts Institute of Technology, Boston, United States
11. Cardiovascular Division, Perelman School for Advanced Medicine, University of Pennsylvania, Philadelphia, USA.

12. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de

Québec, Laval University, Québec (QC), Canada

13. Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland

14. Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital,

Gothenburg, Sweden

15. Department of Laboratory Medicine, Institute of Biomedicine, the Sahlgrenska Academy,

University of Gothenburg, Gothenburg, Sweden

16. Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge,

Cambridge, United Kingdom

17. Nuffield Department of Population Health, University of Oxford, Oxford, United

Kingdom

18. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom

19. Stroke Service, Department of Geriatric Medicine, Mater Misericordiae University

Hospital, Dublin, Ireland

Corresponding author: Stephen Brennan,

Stroke Service, Department of Neurology,

Mater Misericordiae University Hospital, Dublin, Ireland

T: +353-1-803-2000, E: stephen.o.brennan@universityofgalway.ie

Total manuscript word count (including Title Page, Abstract, Text, References, and Figures

Legends): 7621

Abstract

Background: Inflammation is an emerging target for the prevention and treatment of cardiovascular disease (CVD). This drug-target Mendelian randomization (MR) study aimed to predict the on-target effects of IL-18 inhibition on CVD risk. Furthermore, we aimed to explore the effects of IL-18 inhibition on cardio-metabolic traits, cardiac structure, and function, and identify potential adverse outcomes.

Methods: We selected five independent circulating IL-18-lowering variants around the *IL-18* gene locus from the Systematic and Combined AnaLysis of Olink Proteins (SCALLOP) consortium. We then performed two-sample MR analyses to investigate the association of genetically proxied IL-18-inhibition on downstream inflammatory markers, risk of CVD, cardiac magnetic resonance (CMR) imaging measurements of cardiac structure and function, cardiometabolic traits, and a selection of potential adverse effects. We utilized data from the UK Biobank, Cardiogram, GIGASTROKE, and other large genomic consortia (sample range: 3,301-1,320,016).

Results: Following correction for multiple comparisons, one standard deviation (SD) lower in genetically-predicted circulating IL-18 was associated with reductions in downstream biomarkers of IL-18 signaling, including C-reactive protein (SD change -0.02, 95% CI -0.03, -0.02), tumor necrosis factor (SD change -0.19, CI -0.25, -0.14), interferon-gamma (SD change -0.15, CI -0.22, -0.08), and CXCL10 (SD change -0.13, CI -0.16, -0.09). Lower genetically-predicted IL-18 levels were associated with reduced risk of cardioembolic stroke (Odds Ratio [OR] 0.85, CI 0.79-0.92), but not other stroke subtypes. Furthermore, lower genetically predicted IL-18 levels were associated with reduced risk of peripheral arterial disease (OR 0.91, CI 0.84-0.97), atrial fibrillation (OR 0.94, CI 0.89-0.99), and heart failure

(OR 0.84, CI 0.77-0.92), as well as improvements in CMR traits, including a reduction in left

atrial volume (β -0.02, CI -0.03, -0.00). Lower genetically-predicted IL-18 levels were

associated with lower risk of chronic kidney disease, autoimmune diseases, a favorable

cardio-metabolic profile, and higher odds of lung cancer, but not infections.

Conclusions:

Our study provides genetic support that impaired IL-18 signaling may be causally

associated with a lower risk of cardioembolic stroke, possibly mediated through prevention

of cardiac re-modelling, heart failure and atrial fibrillation. IL-18 represents a potential

target for anti-inflammatory therapy in stroke and CVD that warrants further investigation

in clinical trials.

Clinical Perspective

What is new?

- Using multi-omic data, this Mendelian Randomization study provides evidence that IL-18 lowering is associated with a lower lifetime risk of cardiac remodeling, heart failure, and cardioembolic stroke.

- A significant proportion of the protective effect of impaired IL-18 signaling on cardioembolic stroke was mediated through a reduced risk of AF.

What are the clinical implications?

- These data provide compelling evidence that the IL-18 signaling pathway is a promising druggable target for the treatment of heart failure and the prevention of cardioembolic stroke.

- Several monoclonal antibodies targeting IL-18 are in development for the treatment of atopic dermatitis and could be considered for re-purposing for cardiovascular disease.

Abbreviations

HF: Heart failure

NLRP: NOD-like receptor family pyrin domain-containing

AF: Atrial fibrillation

IL-18: Interleukin-18

CMR: Cardiac magnetic resonance

CRP: C-reactive protein

IFN-γ: Interferon-gamma

CVD: cardiovascular disease

MR: Mendelian randomization

GWAS: Genome-wide association study

Introduction

Inflammation has emerged as a promising target for the treatment of atherosclerosis and the secondary prevention of coronary events.[1,2] The first anti-inflammatory trials for secondary prevention after stroke have primarily focused on the therapeutic potential of these agents in patients with atherosclerotic mechanisms and excluded patients with cardioembolic stroke.[3] However, several complementary lines of evidence also support the importance of inflammatory mechanisms in the pathophysiology and progression of heart failure (HF), atrial fibrillation (AF), and cardioembolic stroke. Animal models provide compelling data that the NOD-like receptor family pyrin domain-containing 3 (NLRP) inflammasome is upregulated in cardiomyocytes in the pathogenesis of AF and promotes structural and electrical atrial remodeling.[4] Inflammatory signaling is implicated in several pathways central to the pathophysiology of HF, including mitochondrial dysfunction, calcium homeostasis, cardiac fibrosis, and impaired cardiomyocyte contractility.[5,6] Inflammatory markers are associated with incident AF in population-based studies[7,8] and AF-related stroke.[9] Despite these promising data, the results of the first RCTs of anti-inflammatory therapies in HF,[10,11] and AF[12] have been neutral.

The NLRP3 inflammasome mediates some of its effects through activation of interleukin-1β (IL-1β) via caspase-1 and leads to downstream IL-6 expression. Pre-clinical,[13] observational,[14,15] and genetic studies[16] have coalesced to identify the IL-1β-interleukin-6 (IL-6) signaling pathway as a promising target for risk reduction in cardiovascular disease[17] and stroke.[18] Significantly less attention has been given to the role of interleukin-18 (IL-18), which is also cleaved to its active form by caspase-1 following activation by the NLRP3 inflammasome.[13] IL-18 is a potent pro-inflammatory cytokine that promotes atherosclerotic plaque progression in pre-clinical work.[13] However, experimental data have also

demonstrated that IL-18 signaling plays a key role in cardiomyocyte hypertrophy, ventricular

dysfunction, and cardiac fibrosis.[19-22] Elevated IL-18 levels are observed in patients with HF

and correlate with disease severity, but whether this inflammatory response is a cause or a

consequence of the pathogenesis of HF is unknown.[23] Some, but not all, prospective cohort

studies have reported that IL-18 is associated with incident coronary events[24-26] and HF,[24,27]

but not incident stroke.[24] It remains uncertain whether pharmacological inhibition of the IL-

18 signaling pathway is a viable treatment option for a variety of cardiovascular diseases,

including coronary disease, stroke, AF, and HF.

In the absence of RCTs of therapeutics targeting the IL-18 signaling pathway for the

treatment of cardiovascular disease, genetic studies can offer valuable insights into the on-

target effect of these pharmacological agents.[28,29] Drug-target Mendelian Randomization

(MR) employs genetic variants associated with the levels or activity of drug-target proteins,

thus serving as proxies for pharmacological agents.[29] The primary aim of this study is to

explore the potential benefit of IL-18 inhibition on cardiovascular outcomes using a drug-

target MR approach.

Methods

Study design

We used MR to assess the causal association between genetically proxied downregulation of

IL-18 signaling and: 1) cardiovascular disease outcomes, with replication in non-overlapping

samples where possible; 2) cardiometabolic and inflammatory traits, including cardiac

magnetic resonance (CMR) measures of cardiac structure and function; and 3) potential

adverse and beneficial effects associated with reduced IL-18 signaling. An overview of the

study design is detailed in Figure 1.

200 Initially, we examined the validity of our genetic instrument as a pharmacological proxy for

201 downregulated IL-18 signaling by assessing its impact on established downstream

202 biomarkers: IL-6, C-reactive protein (CRP), interferon-gamma (IFN-γ), and tumor necrosis

203 factor. These biomarkers were identified from pre-clinical[30] and early-phase clinical studies

204 of therapies targeting the IL-18 signaling pathway.[31,32] Circulating levels of IL-1β were

205 selected as a negative control because as IL-1β functions through an alternative signaling

206 pathway, its levels are not expected to be affected by IL-18 signaling. Two-sample *cis*-MR

207 was then used to elucidate the relationship between on-target reduced IL-18 signaling and the

208 risk of cardiovascular disease. Subsequent analyses assessed the bidirectional effects between

209 liability to diseases identified in primary analyses and circulating IL-18 levels. We undertook

210 a mediation analysis to identify pathways that contribute to the effect of genetically predicted

211 IL-18 blockade on cardioembolic stroke. Finally, we explored the effect of downregulated

212 IL-18 signaling on longevity and a selection of clinically relevant outcomes to identify

213 potential adverse outcomes associated with an impaired host immune response. We used

214 parental age at death, a partially heritable trait, as an indirect measure of longevity.[33] IL-18

215 downregulation may have off-target effects beyond cardiovascular outcomes, which is

216 important for assessing the overall safety of therapies targeting IL-18. Given that IL-18 plays

217 a role in immune surveillance, its inhibition could impair the body's ability to detect and

218 eliminate cancer cells, potentially increasing cancer risk. Existing MR evidence has already

219 found an association between higher genetically predicted circulating IL-18 levels and an

220 increased risk of lung cancer.[34]

Instrumental variable selection

Summary statistics for circulating IL-18 concentration were obtained from the Scallop

Consortium's genome-wide association meta-analysis of 90 Olink-measured proteins from 13

contributing cohorts containing 21,758 European individuals.[35] We identified common

(minor allele frequency >0.01) *cis*-genetic variants associated with circulating IL-18

concentration at genome-wide significance from within a 100kb flanking region of the *IL-18*

gene (hg19: chromosome 11: 112013974-112034840). Variants were then clumped using a

linkage disequilibrium (LD) threshold r^2 <0.1 and a distance threshold of 100kb, utilizing

data from the 1000 Genomes Project European reference panel. This methodology selected

five partially correlated *cis*-variants with the strongest association with circulating IL-18

concentration within each LD region from around the *IL-18* gene, as described in

Supplementary Table 2. Instrument strength was assessed through the calculation of an *F*-

statistic and a mean *F*-statistic >10 was considered strong. Strong instruments provide

sufficient statistical power to accurately test hypotheses. Weak instruments, which poorly

predict the exposure, can lead to biased results, particularly in two-sample settings where

they skew findings toward the null, reduce precision, and amplify bias due to violations of

core instrumental variable assumptions.[29] For bidirectional MR analyses, we created

instruments for each cardiometabolic disease by selecting genetic variants associated with

each outcome at genome-wide significance from throughout the genome. We clumped these

variants using an LD threshold of $r^2 < 0.001$ and a distance threshold of 10,000 kb. We

relaxed our significance threshold for HF to 5×10^{-7} due to a scarcity of genome-wide

significant variants.

Data Sources

Detailed information on all data sources used in this study can be found in Table 1,

Supplementary Table 1, and the Supplementary Methods.

Statistical analysis

Mendelian randomization analyses

Causal estimates from MR analyses rely on three key assumptions: (i) relevance, where the

genetic instrument must be associated with the exposure; (ii) independence, where there is no

confounding of the relationship between the instruments and the outcome; and (iii) exclusion

restriction, where the instrument affects the outcome solely through its effect on the

exposure.[36] Random-effects inverse-variance weighted (IVW) models were used in primary

MR analyses. For all significant associations, we conducted a range of sensitivity analyses to

assess for possible violations of the underlying assumptions of MR, including weighted

median and mode to assess for consistency of results, MR Egger to assess for directional

pleiotropy and MR PRESSO to adjust for the effect of potential outliers.[36] We repeated all

analyses using generalized inverse variance weighted MR, which adjusts for residual pairwise

LD among variants included in our IL-18 instrument.[36]

Mediation analysis

We used two-step *cis*-MR to estimate the effect of the exposure on the outcome, conditional

on the mediator (referred to as the "direct' effect, reported as an adjusted OR with respective

95% CI). We then compared this adjusted effect to the unadjusted "total" effect to

qualitatively assess whether substantial attenuation of the effect estimates occurs after

conditioning on the mediator, which would suggest the presence of a mediating pathway. We

only included traits with a biologically plausible mediation mechanism, and for which a valid

genetic instrument could be constructed as a proxy for the potential mediator. We used the

weighted median estimator for the mediation analysis if heterogeneity was detected in the

inverse-variance weighted MR estimate. Two-step cis-MR is particularly useful for

attenuating bias in situations where there are insufficient independent causal variants for

methods like multivariable MR. Otherwise, it is analogous to conventional two-step MR

mediation analysis.

As a secondary complementary approach, we obtained the "indirect" effect and proportion

mediated through the product of coefficients method. The mediated proportion was obtained

by dividing the indirect effect by the total effect and the SE for the indirect effect was

calculated using the delta method.[37] Given the binary nature of some mediators and outcomes

in this study, caution is needed when interpreting the estimated indirect effect and proportion

mediated. These estimates rely on methods that assume additive relationships among the

exposure, mediator, and outcome, which may not be appropriate for binary outcomes.[38]

Colocalization and LD check

Bayesian colocalization was used to determine if levels of circulating IL-18 and our primary

outcomes share a single causal variant at the IL-18 gene locus, which may indicate a causal

pathway between the exposure and the outcome.[39] Colocalization involves calculating

posterior probabilities (PP) for five hypotheses to assess the likelihood that the genetic

variants influencing two traits at a specific locus are overlapping or distinct. H0 suggests that

there is no genetic association with either trait; H1 and H2 suggest that only the first or

second trait has a genetic association; H3 suggests that both traits are associated but have

different causal variants; and H4 suggests that both traits are associated and share a single

causal variant. Colocalization analyses rely on a well-powered outcome GWAS and sufficient

variant coverage in the region of interest.[39,40] A posterior probability (PP) for H3 (distinct

causal variant) and H4 (shared causal variant) less than 0.8, in the context of a statistically

significant MR association, may signal an underpowered outcome GWAS to determine if the

association is due to a shared causal variant or from a confounding variant in LD (i.e.

horizontal pleiotropy).

LD Check is an alternative method for co-localization when variant coverage is insufficient

for Bayesian colocalization.[40] LD Check estimates the LD between the sentinel IL-18 variant

and the top 30 variants from the same genomic region in each outcome study. Causality with

the sentinel IL-18 variant is suggested if at least one of the top 30 SNPs exhibits strong LD

($r^2 > 0.8$).[40] This indicates that these SNPs are highly correlated and may tag the same causal

variant. Such findings provide further evidence of a shared genetic basis, complementing

traditional colocalization methods and the MR findings. While traditional colocalization

methods estimate the probability of a shared causal variant through statistical modeling, LD

checks offer a more direct assessment by leveraging LD structure. This approach is

particularly valuable when the statistical power of colocalization or other methods is limited

due to low SNP coverage."

Reporting and packages

Results from MR analyses are reported as odds ratios (OR) for binary outcomes and standard

deviation (SD) difference for continuous outcomes per SD lower in genetically predicted IL-

18 levels. Results from bidirectional MR analyses are reported as the effect of a one-unit

increase in the log odds of genetic liability for each cardiometabolic disease. We applied the

Benjamini-Hochberg method to control for the false discovery rate (FDR) across all

phenotypes and report the unadjusted and FDR-adjusted p-values. Associations with a

nominal p-value <0.05 and a Benjamini-Hochberg adjusted p-value >0.05 were deemed

suggestive. Associations with a Benjamini-Hochberg adjusted p-value <0.05 were considered

significant. Analyses were performed in R (v4.2.1; R Foundation for Statistical Computing)

with the TwoSampleMR, MendelianRandomisation, Coloc and TwoStepCisMR packages.

Standard Protocol Approvals, Registrations, and Patient Consents

All contributing studies obtained appropriate informed consent from participants and received

ethical approval before commencement. This study was conducted in adherence to the

guidelines for Strengthening the Reporting of Observational Studies in Epidemiology –

Mendelian randomization (STROBE- MR), as detailed in the Supplement.

Data availability

This study utilizes publicly available, summary-level GWAS data that can be accessed

through the GWAS Catalogue (https://www.ebi.ac.uk/gwas/home) and the Integrative

Epidemiology Unit (IEU) OpenGWAS project (https://gwas.mrcieu.ac.uk/) or specific cohort

portals, including The Scallop Consortium (https://zenodo.org/records/2615265), The Centre

for Statistical Genetics (https://csg.sph.umich.edu/willer/public/afib2018/), Pan-UK Biobank

(https://pan.ukbb.broadinstitute.org/), The Human Genetics Amplifier (HuGeAMP)

(https://kp4cd.org/node/169), The Usher Institute of Population Health Sciences and

Informatics (https://datashare.ed.ac.uk/handle/10283/3209), The Cardiovascular Disease

Knowledge Portal (https://cvd.hugeamp.org/downloads.html), The NBDC Human Database

(https://humandbs.dbcls.jp/en/), The Complex Trait Genetics Lab

(https://cncr.nl/research/summary_statistics/) and FinnGen

(https://www.finngen.fi/en/access_results).

Results

Genetically downregulated IL-18 signaling and cardiometabolic biomarkers

Our instrument for lower genetically downregulated IL-18 signaling, composed of 5 variants,

had a mean F-statistic of 124, indicating an appropriate average instrument strength, and

explained 3.64% of the total variation of circulating IL-18 levels in the Scallop Consortium.

Lower genetically predicted IL-18 levels were associated with several downstream

biomarkers of IL-18 signaling, suggesting that our instruments represented a proxy for IL-18

signaling downregulation. The downstream biomarkers that were significantly associated

with genetically proxied IL-18 levels included C-reactive protein (CRP) (SD change -0.02,

95% CI -0.03, -0.02, p_{fdr} <0.001), tumor necrosis factor (SD change -0.19, 95% CI -0.25, -

0.14, p_{fdr} <0.001), interferon-gamma (IFN-y) (SD change -0.15, 95% CI -0.22, -0.08, p_{fdr}

<0.001) and CXCL10 (SD change -0.13, 95% CI -0.16, -0.09, p_{fdr} <0.001), but not IL-1β or

IL-6 (Figure 2). Lower genetically predicted IL-18 levels were associated with lower fasting

insulin (SD change -0.02, 95% CI -0.04, -0.01, p_{fdr} = 0.023), higher diastolic blood pressure

(SD change 0.02, 95% CI 0.02, 0.03, p_{fdr} =<0.001) and body mass index (SD change 0.02,

95% CI 0.02, 0.04, p_{fdr} =0.015), but had no association with lipid subfractions or fasting

glucose.

Genetically downregulated IL-18 signaling and cardiometabolic diseases

Lower genetically predicted IL-18 levels (1 SD decrease in IL-18 levels) were associated

with 15% lower odds of cardioembolic stroke (OR 0.85, 95% CI 0.79-0.92, p_{fdr} <0.001,

Figure 3) and 9% lower odds of peripheral arterial disease (OR 0.91, 95% CI 0.84-0.97, p_{fdr}

=0.026), but had no association with other stroke subtypes, coronary artery disease or aortic

stenosis. In UKB, lower genetically predicted IL-18 levels were also associated with reduced

odds of both all-cause HF (OR 0.83, 95% CI 0.75-0.91, p_{fdr} <0.001) and dilated

cardiomyopathy (OR 0.74, 95% CI 0.58-0.93, p_{fdr} =0.030). When assessing related cardio-

metabolic diseases, lower genetically predicted IL-18 levels were associated with lower odds

of chronic kidney disease (CKD) (OR 0.91, 95% CI 0.84-0.99, p_{fdr}=0.026), and type 2

diabetes mellitus (T2DM) (OR 0.97, 95% CI 0.95-0.99, p_{fdr} = 0.026). Additionally, there was

a trend towards an association between lower genetically predicted IL-18 levels and reduced

risk of AF (OR 0.94, 95% CI 0.89-0.99, p_{fdr} = 0.054), which did not maintain significance

following false discovery rate adjustment. Associations for HF were successfully replicated

in a non-overlapping sample of American cohort studies (OR 0.85, 95% CI 0.75-0.95, p

=0.004, Supplementary Table 3). For AF, results were directionally similar but did not reach

statistical significance in the UK Biobank (UKB) (OR 0.96, 95% CI 0.92-1.00, p = 0.061).

In colocalization analyses between IL-18 and AF, peripheral arterial disease, HF,

cardioembolic stroke, CKD and T2DM, the posterior probabilities of *H3* and *H4* were less

than 0.8 and this along with the low minimum p-values in the *IL-18* gene region in each of

the outcome summary statistics implies suboptimal power for colocalization, the presence of

confounding by LD or multiple causal variants within the gene region. We subsequently

conducted an LD Check analysis and obtained the LD correlation between the sentinel

variant (rs5744249) from the *IL-18* gene locus and the top 30 variants within 100kb of

rs5744249 with the lowest p-values from the cardioembolic stroke, AF, peripheral arterial

disease, HF, CKD and T2DM summary statistics. At least one top *cis*-variant from each

outcome dataset, except for peripheral arterial disease, exhibited strong LD ($r^2 > 0.8$) with

the sentinel variant. This suggests potential causal associations between IL-18 and

cardioembolic stroke, AF, HF, CKD and T2DM.

Genetically downregulated IL-18 signaling and cardiac magnetic resonance imaging traits

In UKB, there were directionally consistent improvements in all measures of cardiac structure and function with lower genetically predicted IL-18 levels as displayed in Figure 3, with the exception of left and right ventricular ejection fractions. Following adjustment for multiple testing, lower genetically predicted IL-18 levels were associated with a reduction in left atrial size (SD change -0.02, 95% CI -0.03, -0.00, p_{fdr} = 0.023) and left ventricular end-systolic volume (SD change -0.08, 95% CI -0.13, -0.02, p_{fdr} = 0.038).

Genetically downregulated IL-18 signaling and potential adverse effects

Lower genetically predicted IL-18 levels were associated with a longer parental lifespan, an indirect measure of longevity (SD change 0.02 years, 95% CI 0.01-0.04, p_{fdr} = 0.005), and reduced risk of a range of autoimmune diseases, including atopic dermatitis (OR 0.86, 95% CI 0.83-0.90, p_{fdr} <0.001), psoriasis (OR 0.84-0.89, p_{fdr} <0.001), asthma (OR 0.90, 95% CI 0.86-0.94, p_{fdr}<0.001), and rheumatoid arthritis (OR 0.85, 95% CI 0.81-0.90, p_{fdr} < 0.001, Figure 4). There was also a trend toward an association between lower genetically predicted IL-18 levels and reduced risk of ulcerative colitis (OR 0.88, 95% CI 0.79-0.98, p_{fdr} = 0.051), which did not maintain significance following false discovery rate adjustment. While lower genetically predicted IL-18 levels were not significantly associated with an increased risk of infection, it was associated with higher odds of lung cancer (OR 1.15, 95% CI 1.11-1.20, p_{fdr} <0.001) and multiple sclerosis (OR 1.17, 95% CI 1.03-1.32, p_{fdr} = 0.039).

Bidirectional relationship between cardiometabolic diseases and IL-18 levels

In reverse MR analyses, genetic liability to cardioembolic stroke was not significantly associated with circulating levels of IL-18 (β representing the effect of one unit increase in

the log odds of genetic liability for cardioembolic stroke -0.03, 95% CI -0.08-0.02, p =

0.267). Similarly, circulating levels of IL-18 were not affected by genetic liability to AF (β

0.00, 95% CI -0.03-0.04, p 0.879), HF (β -0.03, 95% CI -0.22-0.16, p =0.743), CKD (β 0.01,

95% CI -0.07-0.06, p = 0.821), peripheral arterial disease (β 0.07, 96% CI -0.26-0.39, p =

0.686), or higher BMI (β 0.05, 95% CI -0.01-0.12, p = 0.104).

Mediation analyses

We performed separate mediation analyses to quantify the extent to which each downstream

cardiometabolic trait mediates the relationship between IL-18 signaling and cardioembolic

stroke. The association between IL-18 and cardioembolic stroke (unadjusted OR 0.86, 95%

CI 0.79-0.92, p < 0.001) showed attenuation after adjustment for genetic liability to atrial

fibrillation (adjusted OR 0.89, 95% CI 0.80-0.98, p = 0.018), suggesting that a significant

proportion of the causal effect of IL-18 on cardioembolic stroke is mediated through atrial

fibrillation. C-reactive protein and genetic liabilities to HF, CKD, T2DM and obesity had

minimal impact (Supplementary Table 5.1-5.2).

Sensitivity analyses

The MR estimates from generalized IVW, weighted median, weighted mode, MR Egger, and

MR PRESSO are reported in Supplementary Tables 6.1-6.24. No heterogeneity was observed

across all MR analyses, as indicated by Cochrane's Q and Rucker's Q statistics. Estimates

were consistent with primary results when using generalized IVW MR to model residual LD,

and directionally similar across weighted median and weighted mode methods. The p-values

for the MR Egger intercept test and the global MR PRESSO test were not significant,

suggesting an absence of marked pleiotropy.

Discussion

Leveraging data from large-scale genomic, proteomic and imaging studies, we have demonstrated new and important evidence linking IL-18 signaling to HF, peripheral arterial disease, atrial cardiomyopathy, and cardioembolic stroke. Lower genetically predicted IL-18 levels were associated with reduced concentrations of several downstream inflammatory cytokines and exhibited protective effects on cardiac structure and function. Genetic liability to AF and HF mediated a significant proportion of the risk-lowering effect of IL-18 signaling on cardioembolic stroke. Lower genetically predicted IL-18 levels were associated with a favorable metabolic profile overall, with a lower risk of T2DM, CKD, autoimmune disease, and enhanced longevity.

The present data are supported by several lines of evidence from experimental models, observational studies, and emerging data from RCTs implicating the NLRP3-inflammasome and IL-18 activation in HF and AF. The NLRP3-inflammasome is activated by pro-inflammatory mediators, such as IL-1β and TNF-alpha, damage-associated molecular patterns (DAMPs) secondary to ischemia-reperfusion injury, and angiotensin II over-expression from renin-angiotensin activation.[4,21,41] IL-18 activation ensues secondary to NLRP3 inflammasome formation in leukocytes, endothelial cells, fibroblasts, and cardiomyocytes.[21] The binding of IL-18 to its receptor triggers the recruitment of tumor necrosis factor receptor-associated factor-6 (TRAF6), and the activation of nuclear factor Kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK).[21] This cascade results in the synthesis of secondary inflammatory mediators, including IFN-γ and TNF-α.[30] In-vitro and animal models have demonstrated that disrupting the IL-18 signaling pathway can reduce myocardial hypertrophy, improve contractile function, and decrease fibrosis.[21,22] IL-18 mediates β-adrenergic receptor stimulation-induced macrophage infiltration, cardiac

inflammation, and fibrosis.[20] IL-18 also triggers apoptosis in microvascular endothelial cells

through activation of NF-κB and upregulates the expression of osteopontin, fibronectin, and

matrix metalloproteinase 2 (MMP-2) in human cardiac fibroblasts.[21] In humans, IL-18 levels

increase in proportion to disease progression in both HF[23] and AF.[42,43] In the Atherosclerosis

Risk in Communities (ARIC) study circulating IL-18 in mid-life was associated with future

risk of HF.[24] Similarly, Henry et al.'s meta-analysis of four population-based studies

demonstrated an association between IL-18 levels and risk of incident HF.[27]

Our results suggest that the IL-18 signaling pathway is a viable treatment target in AF, HF

and cardioembolic stroke. Our data were derived from non-overlapping cohorts and

demonstrated biologically consistent results, implicating IL-18 at the center of multiple

downstream pro-inflammatory pathways, cardiac remodeling, AF, HF, and ultimately

cardioembolic stroke. Our two-step *cis*-MR analysis suggests that the reduced risk of

cardioembolic stroke associated with downregulated IL-18 signaling is likely mediated

through its protective effects against lifetime cardiac remodeling and AF. Our findings are

supported by Schmidt et al.'s recent cis-MR study, which showed that targeting the IL-18

receptor is associated with four left ventricular CMR traits and risk of dilated

cardiomyopathy in UKB.[44] Additionally, van Vugt et al. replicated an association between

IL-18R and AF across the deCODE, AGES-Reykjavik, and INTERVAL cohorts.[45] In their

candidate gene study, Wang et al. demonstrated that three variants associated with IL18 gene

expression increased risk of AF and left atrial enlargement.[46]

The global burden of stroke, HF and AF is increasing.[47,48] There is a pressing need to identify

and develop disease-modifying therapies that prevent stroke and slow disease progression in

both HF and atrial cardiopathy. In atherosclerosis, colchicine and canakuinumab have both

shown benefit in reducing major adverse cardiovascular events (MACE) in coronary artery

disease.[1,2] Although colchicine did not reduce the risk of MACE after non-cardioembolic

stroke, a 20% reduced risk was observed in an on-treatment analysis suggesting a possible

biological effect.[3] Apart from the treatment of atherosclerosis, there is also increasing interest

in targeting inflammation in HF and AF. Whilst there is some evidence that colchicine

reduces the risk of postoperative AF following cardiac surgery and decreases AF recurrence

after pulmonary vein isolation or ablation[49], a recent RCT was neutral.[12] Currently, no

licensed anti-inflammatory therapies have been proven to prevent hard outcomes in HF.

RCTs investigating the potential of TNFα inhibition were neutral.[10,11] Anakinra, an anti-IL-1

monoclonal antibody, improved several surrogate markers of cardiac function but failed to

significantly reduce hospitalization for HF or death.[50] While genetic studies have identified

the IL-6 signaling pathway as a potential druggable target for AF, they do not support a

causal role in HF or cardioembolic stroke.[16] Consequently, future experimental work and

RCTs should now focus on the potential benefit of IL-18 pathway suppression in the

treatment of HF and the prevention of cardioembolic stroke.

Our results suggest that IL-18 inhibition would likely have a favourable cardio-metabolic

profile. Downregulated IL-18 signaling reduced risk of CKD and T2DM, which are key risk

factors for cardiovascular disease. However, IL-18 suppression was associated with marginal

increases in diastolic blood pressure and BMI, with minimal effects on lipid fractions and

systolic blood pressure. The clinical significance of these findings will need to be further

explored in future studies. The MR estimate for the effect of lower IL-18 signaling on LDL

cholesterol was small and did not reach significance after adjusting for multiple testing (SD

change 0.01, 95% CI 0.00-0.01, p = 0.08). This relationship may not be biologically relevant

and could also be influenced by the large size of the outcome summary statistics. A similar

phenomenon may explain the findings for diastolic blood pressure and BMI. However,

pharmacological therapies can exhibit pleiotropic effects that appear paradoxical despite their

beneficial effect on certain conditions. For example, statins reduce the risk of atherosclerotic

cardiovascular disease by lowering LDL cholesterol levels, while also increasing pro-

atherogenic Lp(a) levels.[51] Similarly, while pre-clinical and MR studies suggest that

inhibiting IL-6 signaling is protective against CVD, clinical trials have shown that IL-6

receptor blockers, such as tocilizumab, increase total cholesterol and LDL cholesterol levels,

which would traditionally be expected to raise CVD risk.[52]

We show that downregulated IL-18 signaling is associated with lower risk of atopic disease,

which supports the rationale for ongoing clinical trials of IL-18 signaling-blocking therapies

in atopic dermatitis. Promising agents for potential repurposing in cardiovascular disease

include GSK1070806 and Camoteskimab, which are human monoclonal antibodies targeting

IL-18, as well as tadekinig α, a recombinant human IL-18 binding protein that sequesters IL-

18. Immunomodulatory therapies carry potential risks, notably with respect to host response

to infections and malignancy. Our study shows that downregulated IL-18 signaling increases

the risk of lung cancer, but not other cancers or infection and is associated with enhanced

lifespan, suggesting a net positive effect on all-cause mortality. The relationship between IL-

18 and lung cancer has been identified in previous MR studies,[34] and a phase 2 clinical trial is

assessing the effect of a decoy-resistant variant of recombinant IL-18 in a range of solid

tumours including non-small cell lung cancer.[53] IL-18 plays a crucial role in cellular

immunity by activating T-helper cells, which stimulate an effective antitumor immune

response. Our results suggest potential cardiometabolic risks associated with using

recombinant IL-18 therapies for cancer treatment, highlighting safety outcomes that should

be monitored in clinical trials. Importantly, we show that reduced IL-18 signaling is

associated with enhanced lifespan, indicative of a net positive effect on all-cause mortality.

Our study suggests a potential causal link between IL-18 inhibition and risks of lung cancer

and multiple sclerosis. However, given the relative rarity of these conditions compared to the

high global burden of stroke and cardiomyopathy, the overall benefits of IL-18 inhibition,

particularly in reducing cardiovascular risk, may outweigh potential risks. Personalized

treatment strategies and risk stratification could help mitigate adverse effects, particularly in

individuals with risk factors for lung cancer or multiple sclerosis. Further clinical research is

necessary to confirm these findings and ensure the long-term safety of IL-18 inhibitors in

diverse populations

Previous data from experimental models and some epidemiological studies suggested that IL-

18 was associated with atherosclerosis and coronary disease.[26,54] For these reasons, we

expected to see an association with atherosclerotic endpoints. However, apart from a modest

association with peripheral arterial disease that did not have LD Check support, we did not

find any compelling evidence that IL-18 signaling is causally associated with atherosclerotic

events. Previous observational data may have been the result of reverse causality whereby IL-

18 expression may have been a consequence of atherosclerotic disease progression rather

than a causal factor. Alternatively, it is also possible that our genetic instrument does not

fully capture compensatory mechanisms that occur within vascular tissues, such as the

upregulation of IL-18 binding protein, which inhibits IL-18 from binding to its receptors and

modulates its biological activity. On the contrary, prior MR studies have implicated IL-6

signaling in coronary artery disease and atherosclerotic stroke.[16] Together with data from

CANTOS suggesting the potential benefit of IL-1β-IL-6 axis suppression,[2] our analysis

supports the rationale of ongoing trials focusing on the high potential of IL-6 pathway

inhibition in atherosclerosis.[17]

Our study has several strengths. The MR study design minimizes bias from reverse causation

and environmental confounders, while cis-MR provides an evaluation of the effects of

directly perturbing a drug target on disease outcomes. We leveraged large multi-omic

datasets to uncover new insights into how downregulated IL-18 signaling influences

cardiovascular disease. Moreover, we developed a robust genetic cis-instrument that mirrors

the effects of reduced IL-18 signaling on downstream biomarkers and conducted a

comprehensive set of mediation and sensitivity analyses to improve confidence in our

findings. We were also able to validate our findings for HF in independent cohorts.

We acknowledge some limitations. Although we utilized large genomic consortia for

outcome summary statistics, our analyses may have been underpowered to detect associations

with rarer phenotypes. Effect sizes derived from drug-target MR studies reflect lifelong

perturbation of the drug target rather than the short-term treatment durations typically seen in

clinical practice, potentially leading to significant differences in the observed benefits. Two-

sample MR methods assume a linear relationship between genetically proxied exposures and

outcomes. In cases of non-linearity, the MR estimates reflect a population average effect

rather than capturing potentially varying effects across different levels of exposure. Similarly,

in clinical practice, the biological response to drugs often requires surpassing a specific

therapeutic dose, a detail that two-sample MR studies might not capture due to their reliance

on average effects. Two-step *cis*-MR relies on several assumptions including linearity, and

may yield unreliable estimates when the mediator or outcome is not continuous, potentially

impacting the accuracy of our effect size estimates and the interpretation of IL-18 signaling

mediation on cardioembolic stroke through AF, HF, CKD, and T2DM. Additionally, using

genetic liability as a proxy for disease may complicate interpretation, as liability does not

equate to actual diagnosis. Our analyses were limited to individuals of European ancestry to

minimize confounding by population stratification and the potential impact of downregulated

IL-18 signaling on risk of cardio-vascular disease in non-European ancestries remains to be

explored. Finally, our MR estimates reflect the impact of downregulated IL-18 signaling on

disease development. However, it remains unclear how appliable these findings are to disease

progression in individuals with established disease, who are more likely to be prioritized for

treatment and included in clinical trials.

In conclusion, this study used large-scale multi-omic data to explore the effects of genetically

downregulated IL-18 signaling on cardiovascular disease. We provide compelling data which

suggests the IL-18 pathway is causally implicated in the evolution of cardiomyopathy, from

structural remodelling through to an increased risk of HF and cardioembolic stroke. These

data strongly suggest that IL-18 represents a viable target for the prevention and treatment of

stroke and heart failure, with a favorable cardiometabolic and autoimmune profile, that

warrants further exploration in clinical trials.

Sources of funding

PJK has received funding from the Irish Health Research Board. DG is supported by the

British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College

London.

Disclosures

The authors have no relevant conflicts of interest to disclose.

References

1. Xia M, Yang X, Qian C. Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease. *Am J Cardiol*. 2021;140:33-38. doi: 10.1016/j.amjcard.2020.10.043
2. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *New England Journal of Medicine*. 2017;377:1119-1131.
3. Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, Collins R, Cronin S, Czlonkowska A, Desfontaines P. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. *The Lancet*. 2024.
4. Yao C, Veleva T, Scott L, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I, et al. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. *Circulation (New York, NY)*. 2018;138:2227-2242. doi: 10.1161/CIRCULATIONAHA.118.035202
5. McKechnie DGJ, Papacosta AO, Lennon LT, Welsh P, Whincup PH, Wannamethee SG. Inflammatory Markers and Incident Heart Failure in Older Men: the Role of Nt-Probnp. *Biomarkers in Medicine*. 2021;15:413-425. doi: 10.2217/bmm-2020-0669
6. Szabo TM, Frigy A, Nagy EE. Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. *Int J Mol Sci*. 2021;22. doi: 10.3390/ijms222313053
7. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, Buring JE, Albert CM. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. *Eur Heart J*. 2010;31:1730-1736. doi: 10.1093/eurheartj/ehq146
8. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation*. 2003;108:3006-3010. doi: 10.1161/01.CIR.0000103131.70301.4F
9. Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. *Am Heart J*. 2015;170:1151-1160. doi: 10.1016/j.ahj.2015.09.018
10. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation*. 2004;109:1594-1602. doi: 10.1161/01.Cir.0000124490.27666.B2
11. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation*. 2003;107:3133-3140. doi: 10.1161/01.Cir.0000077913.60364.D2

669   12.   Benz AP, Amit G, Connolly SJ, Singh J, Acosta-Vélez JG, Conen D, Deif B,
670   Divakaramenon S, McIntyre WF, Mtwesi V, et al. Colchicine to Prevent Atrial
671   Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-
672   Controlled Trial. *Circulation: Arrhythmia and Electrophysiology*. 2024;17:e01238.
673   doi: doi:10.1161/CIRCEP.123.012387
674   13.   Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1
675   and the inflammasome as therapeutic targets in cardiovascular disease.
676   *Circulation research*. 2020;126:1260-1280.
677   14.   Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di
678   Angelantonio E, Gudnason V, Rumley A, Lowe GD, et al. Inflammatory cytokines
679   and risk of coronary heart disease: new prospective study and updated meta-
680   analysis. *Eur Heart J*. 2014;35:578-589. doi: 10.1093/eurheartj/eht367
681   15.   Papadopoulos A, Palaiopanos K, Bjorkbacka H, Peters A, de Lemos JA, Seshadri
682   S, Dichgans M, Georgakis MK. Circulating Interleukin-6 Levels and Incident
683   Ischemic Stroke: A Systematic Review and Meta-analysis of Prospective Studies.
684   *Neurology*. 2021. doi: 10.1212/WNL.0000000000013274
685   16.   Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M, Invent
686   Consortium CIWG. Interleukin-6 Signaling Effects on Ischemic Stroke and Other
687   Cardiovascular Outcomes: A Mendelian Randomization Study. *Circ Genom
688   Precis Med*. 2020;13:e002872. doi: 10.1161/CIRCGEN.119.002872
689   17.   Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in
690   Cardiovascular Disease. *Circ Res*. 2021;128:1728-1746. doi:
691   10.1161/CIRCRESAHA.121.319077
692   18.   McCabe JJ, Walsh C, Gorey S, Harris K, Hervella P, Iglesias-Rey R, Jern C, Li L,
693   Miyamoto N, Montaner J, et al. C-Reactive Protein, Interleukin-6, and Vascular
694   Recurrence After Stroke: An Individual Participant Data Meta-Analysis. *Stroke*.
695   2023. doi: 10.1161/STROKEAHA.122.040529
696   19.   Toldo S, Mezzaroma E, O'Brien L, Marchetti C, Seropian IM, Voelkel NF, Van
697   Tassell BW, Dinarello CA, Abbate A. Interleukin-18 mediates interleukin-1-
698   induced cardiac dysfunction. *Am J Physiol Heart Circ Physiol*. 2014;306:H1025-
699   1031. doi: 10.1152/ajpheart.00795.2013
700   20.   Xiao H, Li H, Wang J-J, Zhang J-S, Shen J, An X-B, Zhang C-C, Wu J-M, Song Y,
701   Wang X-Y, et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-
702   adrenergic insult. *European Heart Journal*. 2017;39:60-69. doi:
703   10.1093/eurheartj/ehx261
704   21.   O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A,
705   Toldo S. Interleukin-18 as a therapeutic target in acute myocardial infarction and
706   heart failure. *Mol Med*. 2014;20:221-229. doi: 10.2119/molmed.2014.00034
707   22.   Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF. IL-18
708   induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in
709   mice. *Am J Physiol Heart Circ Physiol*. 2009;297:H76-85. doi:
710   10.1152/ajpheart.01285.2008
711   23.   Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T. Circulating
712   levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine
713   imbalance exaggerates the pathophysiology of advanced heart failure. *J Card
714   Fail*. 2002;8:21-27. doi: 10.1054/jcaf.2002.31628

24.   Jia X, Buckley L, Sun C, Al Rifai M, Yu B, Nambi V, Virani SS, Selvin E, Matsushita
K, Hoogeveen RC, et al. Association of interleukin-6 and interleukin-18 with
cardiovascular disease in older adults: Atherosclerosis Risk in Communities
study. *European Journal of Preventive Cardiology*. 2023;30:1731-1740. doi:
10.1093/eurjpc/zwad197

25.   Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di
Angelantonio E, Gudnason V, Rumley A, Lowe GDO, et al. Inflammatory
cytokines and risk of coronary heart disease: new prospective study and
updated meta-analysis. *European Heart Journal*. 2013;35:578-589. doi:
10.1093/eurheartj/eht367

26.   Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE,
Woodward M, Lennon LT, Thomson A, Welsh P, Rumley A, et al. Interleukin 18
and coronary heart disease: prospective study and systematic review.
Atherosclerosis. 2011;217:227-233. doi: 10.1016/j.atherosclerosis.2011.03.015

27.   Henry A, Gordillo-Marañón M, Finan C, Schmidt AF, Ferreira JP, Karra R,
Sundström J, Lind L, Ärnlöv J, Zannad F. Therapeutic targets for heart failure
identified using proteomics and Mendelian randomization. *Circulation*.
2022;145:1205-1217.

28.   Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic
evidence on clinical success. *Nature*. 2024;629:624-629. doi: 10.1038/s41586-
024-07316-0

29.   Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, Finan C,
Hingorani AD, Howson JM, Burgess S. Mendelian randomization for studying the
effects of perturbing drug targets. *Wellcome open research*. 2021;6.

30.   Kaplanski G. Interleukin-18: Biological properties and role in disease
pathogenesis. *Immunological reviews*. 2018;281:138-153.

31.   Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J,
Schaeverbeke T, Hamidou MA, et al. Open-label, multicentre, dose-escalating
phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-
onset Still's disease. *Annals of the Rheumatic Diseases*. 2018;77:840-847. doi:
10.1136/annrheumdis-2017-212608

32.   Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN,
Thurmond LM, Weisenbach J, Dar MM. A dose-escalation study of recombinant
human interleukin-18 using two different schedules of administration in patients
with cancer. *Clinical Cancer Research*. 2008;14:3462-3469.

33.   Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, Ruth KS, Tuke
MA, Yaghootkar H, Wood AR. Human longevity is influenced by many genetic
variants: evidence from 75,000 UK Biobank participants. *Aging (Albany NY)*.
2016;8:547.

34.   Bouras E, Karhunen V, Gill D, Huang J, Haycock PC, Gunter MJ, Johansson M,
Brennan P, Key T, Lewis SJ. Circulating inflammatory cytokines and risk of five
cancers: a Mendelian randomization analysis. *BMC medicine*. 2022;20:1-15.

35.   Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, Page K,
Zhernakova DV, Wu Y, Peters J. Genomic and drug target evaluation of 90
cardiovascular proteins in 30,931 individuals. *Nature metabolism*. 2020;2:1135-
1148.

36.   Richmond RC, Smith GD. Mendelian randomization: concepts and scope. *Cold*
Spring Harbor perspectives in medicine. 2022;12:a040501.
37.   Woolf B, Zagkos L, Gill D. TwoStepCisMR: a novel method and R package for
attenuating bias in cis-mendelian randomization analyses. *Genes*.
2022;13:1541.
38.   Burgess S, Thompson DJ, Rees JM, Day FR, Perry JR, Ong KK. Dissecting causal
pathways using Mendelian randomization with summarized genetic data:
application to age at menarche and risk of breast cancer. *Genetics*.
2017;207:481-487.
39.   Zuber V, Grinberg NF, Gill D, Manipur I, Slob EA, Patel A, Wallace C, Burgess S.
Combining evidence from Mendelian randomization and colocalization: Review
and comparison of approaches. *The American Journal of Human Genetics*.
2022;109:767-782.
40.   Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A,
Erola P, Liu Y, Luo S. Phenome-wide Mendelian randomization mapping the
influence of the plasma proteome on complex diseases. *Nature genetics*.
2020;52:1122-1131.
41.   Mezzaroma E, Abbate A, Toldo S. The inflammasome in heart failure. *Curr Opin*
Physiol. 2021;19:105-112. doi: 10.1016/j.cophys.2020.09.013
42.   Liu Y, Luo D, Liu E, Liu T, Xu G, Liang X, Yuan M, Zhang Y, Chen X, Chen X.
MiRNA21 and IL-18 levels in left atrial blood in patients with atrial fibrillation
undergoing cryoablation and their predictive value for recurrence of atrial
fibrillation. *Journal of Interventional Cardiac Electrophysiology*. 2022;64:111-120.
43.   Luan Y, Guo Y, Li S, Yu B, Zhu S, Li S, Li N, Tian Z, Peng C, Cheng J. Interleukin-18
among atrial fibrillation patients in the absence of structural heart disease.
Europace. 2010;12:1713-1718.
44.   Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, van der
Laan SW, Gross C, Clarkson C, Henry A. Druggable proteins influencing cardiac
structure and function: Implications for heart failure therapies and cancer
cardiotoxicity. *Science advances*. 2023;9:eadd4984.
45.   van Vugt M, Finan C, Chopade S, Providencia R, Bezzina CR, Asselbergs FW, van
Setten J, Schmidt AF. Integrating metabolomics and proteomics to identify novel
drug targets for heart failure and atrial fibrillation. *Genome Medicine*.
2024;16:120.
46.   Wang Y-H, Fu L, Wang B, Li S-F, Sun Z, Luan Y. Genetic variants of interleukin-18
are associated with reduced risk of atrial fibrillation in a population from
Northeast China. *Gene*. 2017;626:269-274.
47.   Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global
burden of heart failure: a comprehensive and updated review of epidemiology.
Cardiovascular research. 2022;118:3272-3287.
48.   Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016:
a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*
Neurol. 2019;18:439-458. doi: 10.1016/S1474-4422(19)30034-1
49.   Kommu S, Arepally S. The effect of colchicine on atrial fibrillation: a systematic
review and meta-analysis. *Cureus*. 2023;15.
50.   Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C,
Abouzaki NA, Dixon D, Kadariya D, Christopher S. Interleukin-1 blockade in

recently decompensated systolic heart failure: results from REDHART (Recently
Decompensated Heart Failure Anakinra Response Trial). *Circulation: Heart*
Failure. 2017;10:e004373.

51.   Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL. Statin therapy increases
lipoprotein (a) levels. *European heart journal*. 2020;41:2275-2284.

52.   Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF.
Integrated safety in tocilizumab clinical trials. *Arthritis Research & Therapy*.
2011;13:R141. doi: 10.1186/ar3455

53.   Moser JC, Sullivan R, Taylor MH, Puzanov I, Falchook GS, Sznol M, Paton VE,
Chonzi D, Garofalo B, Sonnemann M, et al. 736 A phase 1/2 open-label, dose-
escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a
monotherapy and with pembrolizumab in advanced solid tumor malignancies.
Journal for ImmunoTherapy of Cancer. 2023;11:A829-A829. doi: 10.1136/jitc-
2023-SITC2023.0736

54.   Wang J, Sun C, Gerdes N, Liu C, Liao M, Liu J, Shi MA, He A, Zhou Y, Sukhova GK,
et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18
receptor and the Na-Cl co-transporter. *Nature Medicine*. 2015;21:820-826. doi:
10.1038/nm.3890

Table 1. Overview of the cardiometabolic disease summary statistics used in this study.

Figure 1. Overview of the study design.

Stage 1 includes a graphical depiction of the interleukin-18 signaling pathway and a Manhattan plot illustrating the genome-wide association study of circulating concentration of interleukin-18 in the Scallop consortium. The red line indicates the genome-wide significance threshold (5×10^{-8}).

Figure 2. The association between genetically downregulated IL-18 signaling and cardiometabolic biomarkers

Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation; FDR, false discovery rate; CXCL10, C-X-C motif chemokine ligand 10.

Figure 3. The association between genetically downregulated IL-18 signaling and cardiometabolic diseases.

Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.

Figure 4. The association between genetically downregulated IL-18 signaling and cardiac magnetic resonance imaging traits.

Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.

Figure 5. The association between genetically downregulated IL-18 signaling and oncological, autoimmune, neurological, and infectious diseases

Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.

Instrument Selection

Circulating levels of IL-18
in the Scallop Consortium

Two-sample Mendelian Randomization

Step 2

Genetically proxied
IL-18 inhibition

Metabolic traits   Cardiovascular disease

CMR traits   Adverse effects

Exploratory Two-step Mediation

Step 3

CVD mediators

IL-18   Cardioembolic stroke

Exposure / Outcome	Total Sample Size	Case / Controls	PMID
IL-18 levels	21,758	NA	33067605
Heart failure	394,156	6,504 / 387,652	30586722
Dilated cardiomyopathy	6,584	1,303 / 5,281	38036550
Atrial fibrillation (without UKB)	635,097	45,800 / 589,297	30061737
All ischaemic stroke	1,296,908	62,100 / 1,234,808	36180795
Small vessel stroke	1,241,619	6,811 / 1,234,808	36180795
Large artery stroke	1,241,207	6,399 / 1,234,808	36180795
Cardioembolic stroke	1,245,612	10,804 / 1,234,808	36180795
Coronary artery disease	1,165,690	181,522 / 984,168	36474045
Peripheral arterial disease	461,634	12,086 / 449,548	34601942
Atrioventricular block	318,251	6,097 / 312,154	36653562
Left bundle branch block	314,284	2,130 / 312,154	36653562
Right bundle branch block	313,200	1,046 / 312,154	36653562
Abdominal aortic aneurysm	1,264,891	8,163 / 1,256,755	36777996
Aortic stenosis	412,181	9,870 / 402,311	36653562
Chronic kidney disease	625,219	64,164 / 561,055	31152163
Type 2 diabetes mellitus	898,130	74,124 / 824,006	30297969

Outcome	OR (95% CI)	P-val
Coronary artery disease	1.00 (0.97, 1.02)	0.846
Peripheral artery disease	0.91 (0.84, 0.97)	0.026
Aortic stenosis	1.01 (0.91, 1.11)	0.933
All-cause heart failure	0.83 (0.76, 0.91)	<0.001
Non-ischaemic heart failure	0.75 (0.59, 0.95)	0.051
Dilated cardiomyopathy	0.74 (0.58, 0.93)	0.030
Large artery stroke	1.03 (0.89, 1.20)	0.789
Cardioembolic stroke	0.85 (0.79, 0.92)	<0.001
Small vessel stroke	1.08 (0.93, 1.25)	0.441
All ischaemic stroke	1.02 (0.99, 1.05)	0.343
Atrial fibrillation	0.93 (0.88, 0.99)	0.054
Left bundle branch block	1.00 (0.91, 1.09)	0.963
Right bundle branch block	0.96 (0.80, 1.16)	0.821
Atrioventricular block	1.01 (0.91, 1.12)	0.933
Abdominal aortic aneurysm	1.00 (0.95, 1.05)	0.933
Chronic kidney disease	0.91 (0.84, 0.97)	0.026
Type 2 diabetes mellitus	0.97 (0.95, 0.99)	0.026

0.60 0.70 0.80 0.90 1.0 1.1 1.2 1.3
Odds Ratio per SD lower in IL-18 levels (95% CI)

Outcome	Beta (95% CI)	P–val
C–reactive protein	−0.02 (−0.03, −0.02)	<0.001
Tumour necrosis factor	−0.19 (−0.25, −0.14)	<0.001
Interferon gamma	−0.15 (−0.22, −0.08)	<0.001
Interleukin 6	−0.05 (−0.11, 0.02)	0.246
CXCL10	−0.13 (−0.16, −0.09)	<0.001
Total LDL–C	0.01 (0.00, 0.01)	0.076
Total HDL–C	−0.00 (−0.01, 0.00)	0.618
Triglycerides	0.00 (0.00, 0.01)	0.096
Apolipoprotein B	−0.00 (−0.03, 0.03)	0.968
Apolipoprotein A1	−0.02 (−0.04, −0.00)	0.096
Systolic blood pressure	0.01 (−0.01, 0.02)	0.565
Diastolic blood pressure	0.02 (0.02, 0.03)	<0.001
Body mass index	0.02 (0.01, 0.04)	0.015
HbA1c	−0.00 (−0.01, 0.00)	0.554
Fasting glucose	0.01 (−0.00, 0.03)	0.106
Fasting insulin	−0.02 (−0.04, −0.01)	0.023

−0.25 −0.15 −0.05 0.05
Change per SD lower in IL−18 levels (95% CI)

Outcome	Beta (95% CI)	P–val
Left atrial volume	−0.02 (−0.03, −0.00)	0.022
Left ventricular end systolic volume	−0.08 (−0.13, −0.02)	0.039
Left ventricular end distolic volume	−0.04 (−0.08, 0.00)	0.108
Left ventricular ejection fraction	0.03 (−0.02, 0.08)	0.448
Right ventricular end systolic volume	−0.02 (−0.04, 0.00)	0.124
Right ventricular end diastolic volume	−0.02 (−0.05, 0.01)	0.269
Right ventricular ejection fraction	0.02 (−0.03, 0.06)	0.630
T1 myocardial fibrosis	−0.01 (−0.04, 0.01)	0.304

−0.2 −0.1 0 0.1

Change per SD lower in IL−18 levels (95% CI)

Outcome	OR (95% CI)	P-val
Cancer		
Lung cancer	1.15 (1.11, 1.20)	<0.001
Breast cancer	0.94 (0.87, 1.02)	0.239
Prostate cancer	1.02 (0.95, 1.09)	0.717
Colorectal cancer	1.05 (0.88, 1.27)	0.731
Autoimmune		
Atopic dermatitis	0.86 (0.83, 0.90)	<0.001
Psoriasis	0.84 (0.80, 0.89)	<0.001
Asthma	0.90 (0.86, 0.94)	<0.001
Rheumatoid arthritis	0.85 (0.81, 0.90)	<0.001
Ulcerative colitis	0.88 (0.79, 0.98)	0.051
Crohn's disease	0.99 (0.85, 1.15)	0.933
Neurological		
Multiple sclerosis	1.17 (1.03, 1.32)	0.039
Alzheimer's disease	1.03 (0.92, 1.16)	0.758
Migraine	0.98 (0.84, 1.16)	0.933
Parkinson's disease	1.09 (0.96, 1.23)	0.293
Infectious		
Sepsis	0.94 (0.86, 1.03)	0.343
Pneumonia	1.07 (0.99, 1.15)	0.147
Cellulitis	0.98 (0.91, 1.05)	0.653
Urinary tract infection	1.07 (1.00, 1.14)	0.103
Tuberculosis	0.97 (0.81, 1.14)	0.820

0.80 0.90 1.0 1.1 1.2 1.3
Odds Ratio per SD lower in IL−18 levels (95% CI)